Q3 2016 Earnings Forecast for Johnson & Johnson Issued By Jefferies Group (JNJ)
Johnson & Johnson (NYSE:JNJ) – Equities researchers at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for Johnson & Johnson in a report released on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will earn $1.71 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $115.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2016 earnings at $6.72 EPS and FY2017 earnings at $6.78 EPS.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%.
Several other research analysts also recently commented on the stock. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 price target for the company in a report on Monday, October 3rd. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Credit Suisse Group AG reissued a “neutral” rating and issued a $123.00 price target on shares of Johnson & Johnson in a report on Monday, September 19th. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $120.19.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 117.56 on Friday. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07. The company has a market cap of $321.63 billion, a PE ratio of 21.91 and a beta of 0.62. The firm’s 50-day moving average is $118.72 and its 200-day moving average is $117.37.
In related news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Large investors have recently bought and sold shares of the company. Americafirst Capital Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $127,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.